-$0.48 Earnings Per Share Expected for IDEAYA Biosciences, Inc. (NASDAQ:IDYA) This Quarter

Wall Street brokerages forecast that IDEAYA Biosciences, Inc. (NASDAQ:IDYAGet Rating) will report ($0.48) earnings per share for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for IDEAYA Biosciences’ earnings. The highest EPS estimate is ($0.25) and the lowest is ($0.68). IDEAYA Biosciences reported earnings of ($0.33) per share during the same quarter last year, which would indicate a negative year over year growth rate of 45.5%. The business is expected to announce its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that IDEAYA Biosciences will report full-year earnings of ($1.49) per share for the current year, with EPS estimates ranging from ($1.88) to ($0.86). For the next financial year, analysts expect that the company will report earnings of ($2.28) per share, with EPS estimates ranging from ($2.83) to ($1.64). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for IDEAYA Biosciences.

IDEAYA Biosciences (NASDAQ:IDYAGet Rating) last announced its quarterly earnings data on Tuesday, May 10th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.05. IDEAYA Biosciences had a negative net margin of 170.82% and a negative return on equity of 19.08%.

Several research firms have recently commented on IDYA. Stifel Nicolaus raised shares of IDEAYA Biosciences from a “hold” rating to a “buy” rating and decreased their price target for the company from $27.00 to $20.00 in a report on Thursday, March 10th. Wedbush restated an “outperform” rating and issued a $34.00 target price on shares of IDEAYA Biosciences in a research note on Wednesday, March 16th. Finally, Zacks Investment Research upgraded IDEAYA Biosciences from a “sell” rating to a “hold” rating in a research report on Friday, March 18th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, IDEAYA Biosciences currently has an average rating of “Buy” and a consensus price target of $29.40.

Large investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC bought a new position in shares of IDEAYA Biosciences in the third quarter valued at approximately $6,835,000. Rafferty Asset Management LLC acquired a new stake in IDEAYA Biosciences in the third quarter worth approximately $802,000. Dimensional Fund Advisors LP bought a new position in IDEAYA Biosciences during the 3rd quarter valued at $2,337,000. Deutsche Bank AG increased its position in shares of IDEAYA Biosciences by 13.1% during the 3rd quarter. Deutsche Bank AG now owns 18,844 shares of the company’s stock valued at $480,000 after purchasing an additional 2,181 shares during the period. Finally, AXA S.A. raised its stake in shares of IDEAYA Biosciences by 16.1% in the 3rd quarter. AXA S.A. now owns 278,733 shares of the company’s stock worth $7,105,000 after buying an additional 38,626 shares in the last quarter. 89.79% of the stock is owned by institutional investors.

Shares of IDYA opened at $10.47 on Friday. IDEAYA Biosciences has a 52 week low of $8.14 and a 52 week high of $28.00. The firm has a market cap of $404.42 million, a price-to-earnings ratio of -7.12 and a beta of 1.78. The stock has a 50 day moving average of $11.01 and a 200-day moving average of $16.43.

IDEAYA Biosciences Company Profile (Get Rating)

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations.

Further Reading

Get a free copy of the Zacks research report on IDEAYA Biosciences (IDYA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for IDEAYA Biosciences (NASDAQ:IDYA)

Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.